Paroxysmal hemicrania is a rare, intensely painful headache disorder defined by short but frequent attacks of strictly one-sided head pain accompanied by visible autonomic symptoms on the same side of the face. Attacks typically last under 20 minutes on average, can strike more than ten times a day, and respond almost completely to a single anti-inflammatory drug called indomethacin. That drug response is so central to the condition that it serves as both treatment and diagnostic test, yet the disorder is widely under-recognized and frequently mistaken for other headaches, sometimes for years.
What Paroxysmal Hemicrania Feels Like
The pain is severe and usually centered around the eye, temple, and forehead on one side of the head, though it can spread to the back of the head, the jaw, the ear, and even the shoulder. In a prospective study of 31 patients, the most common pain locations were the orbital and temporal regions (reported by about three-quarters of patients), with retro-orbital pain in roughly six out of ten and frontal pain in just over half. Pain in the back of the head, the upper jaw area, and the neck was reported by a substantial minority as well.1Oxford Academic (Brain). Paroxysmal hemicrania: a prospective clinical study of 31 cases
What makes the condition unmistakable once you know what to look for is the cluster of autonomic symptoms that accompany each attack. Tearing of the eye on the painful side is the most common, followed by redness of the eye, a runny nose, nasal congestion, drooping of the eyelid, and flushing of the face. In that same 31-patient study, nearly nine out of ten patients had tearing, about seven in ten had conjunctival injection, and over half had a runny or blocked nose.2Oxford Academic (Brain). Paroxysmal hemicrania: a prospective clinical study of 31 cases Restlessness or agitation during attacks is also recognized as a feature and was recently added to the international diagnostic criteria.3Neurology India. Paroxysmal Hemicrania
The pain is “side-locked,” meaning it stays on the same side of the head from attack to attack. This is an important clue because many other headache types can alternate sides. Attacks tend to cluster throughout the day, with a mean frequency of around 11 per day in that prospective series, and each episode lasts roughly 17 minutes on average.4Oxford Academic (Brain). Paroxysmal hemicrania: a prospective clinical study of 31 cases
Why Indomethacin Matters So Much
For almost no other headache disorder is a single medication so tightly woven into the definition itself. To formally meet the diagnostic criteria for paroxysmal hemicrania, your headaches must respond completely to indomethacin at appropriate doses. This isn’t just a treatment preference; it’s a diagnostic requirement. Researchers have described this response as the “sine qua non” of the condition, and it remains one of the most reliable distinguishing features in headache medicine.5Brain. Paroxysmal hemicrania: a prospective clinical study of 31 cases
In practice, when a headache specialist suspects paroxysmal hemicrania, an indomethacin trial functions as a diagnostic tool. You take the drug, and if the attacks stop completely, that confirms the diagnosis. This “indotest” is remarkably clean as medical tests go: the response is often dramatic and swift, with attacks ceasing within a day or two of reaching an effective dose.
What makes indomethacin special compared to other anti-inflammatory drugs isn’t entirely clear. It belongs to the same broad family as ibuprofen and naproxen, yet those relatives typically don’t work for paroxysmal hemicrania. Research has explored its unique effects on nitric oxide pathways and specific inflammatory mediators, but no single mechanism fully explains why indomethacin succeeds where closely related drugs fail.6PubMed Central. Differential actions of indomethacin: clinical relevance in headache That pharmacological mystery is one reason paroxysmal hemicrania and related conditions are sometimes grouped together as “indomethacin-responsive headaches.”
How Common Is It
Paroxysmal hemicrania is rare, but how rare depends on who’s counting and where. A Norwegian population-based registry study found a one-year prevalence of about 1.4 per 100,000 adults.7PubMed Central. One-year prevalence of cluster headache, hemicrania continua, paroxysmal hemicrania and SUNCT in Norway: a population-based nationwide registry study A larger retrospective analysis of U.S. electronic health records found a considerably higher five-year prevalence of about 22 per 100,000, which likely reflects a different time window, different diagnostic capture, and the tendency for chronic cases to accumulate in health-record databases.8PubMed Central. Prevalence, demographics, comorbidities, and treatment patterns of patients with the trigeminal autonomic cephalalgias: a retrospective analysis of United States electronic health records
Across both studies, paroxysmal hemicrania was considerably less common than cluster headache but more common than a related condition called SUNCT. Both studies also found the condition to be more common in women than men, which is a notable departure from cluster headache, where men have historically been thought to predominate (though recent data is challenging that assumption too).9PubMed Central. One-year prevalence of cluster headache, hemicrania continua, paroxysmal hemicrania and SUNCT in Norway: a population-based nationwide registry study The true prevalence is almost certainly underestimated because so many cases go unrecognized, a problem covered in detail later in this article.
How It Differs from Cluster Headache and Other Similar Conditions
Paroxysmal hemicrania belongs to a family of headache disorders called the trigeminal autonomic cephalalgias, which share the combination of one-sided head pain and autonomic symptoms. The family includes cluster headache, SUNCT/SUNA (short-lasting unilateral neuralgiform headache attacks), and hemicrania continua. Despite their shared features, these conditions differ in ways that matter for treatment.10PubMed. Paroxysmal hemicrania, SUNCT, and hemicrania continua
The clearest distinctions come from attack duration, frequency, and drug response. Paroxysmal hemicrania sits in the middle: its attacks are longer than SUNCT’s (which are typically seconds to minutes) but far shorter than cluster headache’s (which usually last 15 minutes to three hours). Attack frequency in paroxysmal hemicrania is higher than in cluster headache but lower than in SUNCT, which can produce dozens or even hundreds of attacks per day. Hemicrania continua, meanwhile, is a continuous baseline headache with superimposed flare-ups rather than discrete episodes.11PubMed. Trigeminal autonomic cephalalgias: paroxysmal hemicrania, SUNCT/SUNA, and hemicrania continua
The distinction from cluster headache is the one that matters most in practice, because cluster headache is far better known and is frequently the first diagnosis a patient receives. A study comparing the two found that maximal pain location differed: cluster headache patients tended to report pain centered in and around the eye, while paroxysmal hemicrania patients more often reported the worst pain outside the eye. Mean attack duration was longer and mean attack frequency was lower in cluster headache. Other features like nocturnal attacks, tenderness between attacks, and even response to verapamil did not reliably distinguish the two.12PubMed. Cluster headache and paroxysmal hemicrania: differential diagnosis That overlap is exactly why the indomethacin trial is so important: it’s the cleanest separator.
The Problem of Misdiagnosis
Paroxysmal hemicrania is frequently missed or mislabeled, and not just by general practitioners. A systematic review of diagnostic errors across the trigeminal autonomic cephalalgias found that even neurologists and headache specialists regularly failed to recognize these conditions. Patients were most commonly misdiagnosed with migraine, trigeminal neuralgia, sinus infection, dental pain, or temporomandibular dysfunction. These errors led to years of ineffective treatment and, in some cases, unnecessary invasive procedures.13PubMed Central. Diagnostic and therapeutic errors in trigeminal autonomic cephalalgias and hemicrania continua: a systematic review
The root of the problem is awareness. Paroxysmal hemicrania is rare enough that many clinicians never encounter it during training. When a patient presents with severe, recurring one-sided headaches, the reflex is to reach for diagnoses that are orders of magnitude more common, like migraine or cluster headache. A migraine diagnosis can seem plausible because the pain is severe and one-sided; a sinus diagnosis gets considered because of the nasal congestion and tearing. The cascade of wrong diagnoses means that many patients receive triptans, oxygen therapy, or even sinus surgery before anyone thinks to try indomethacin.
If you have short, frequent, strictly one-sided headaches with visible autonomic symptoms on the painful side, and standard migraine treatments aren’t working, it’s worth explicitly asking your doctor about an indomethacin trial. The response is dramatic enough that the diagnosis becomes clear within days.
What Happens in the Brain During an Attack
Functional brain imaging during paroxysmal hemicrania attacks has pointed to the hypothalamus as a key player. In a study using PET scanning, untreated attacks were associated with significant activation of the hypothalamus on the opposite side of the brain from the pain, along with activation in the ventral midbrain extending over structures involved in pain processing.14PubMed. Posterior hypothalamic activation in paroxysmal hemicrania This finding is striking because the hypothalamus also lights up during cluster headache attacks, suggesting that all trigeminal autonomic cephalalgias share a common generator deep in the brain, even though their clinical profiles differ.
The hypothalamus is the brain’s central clock, regulating circadian rhythms, hormone cycles, and autonomic function. Its involvement may explain why these headaches tend to follow rhythmic patterns and produce such prominent autonomic symptoms. But having a shared generator doesn’t mean the conditions are identical; they likely differ in which downstream pathways get activated and how those pathways interact with pain-modulating circuits. The specific sensitivity to indomethacin in paroxysmal hemicrania and hemicrania continua suggests a distinct neurochemical flavor within that shared architecture.
Long-Term Treatment and Tolerability
Because paroxysmal hemicrania is often a chronic condition, most people end up taking indomethacin for years or even decades. The good news is that long-term use appears to be reasonably well tolerated. A study tracking patients on prolonged indomethacin treatment found that about one in four experienced side effects, mostly gastrointestinal, and these were generally manageable with a stomach-protecting drug like ranitidine. No major adverse events were observed. Many patients were able to reduce their dose over time, with reductions of up to 60% from the initial effective dose while still maintaining headache control.15PubMed. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua
Still, indomethacin carries the same risks as other drugs in its class: stomach ulcers, kidney strain, and cardiovascular concerns with prolonged use, particularly in older adults. Periodic monitoring and the use of the lowest effective dose are standard practice. The ability to taper the dose in many patients is reassuring, because it means the condition doesn’t necessarily require the same high doses indefinitely.
When Indomethacin Isn’t an Option
A minority of patients cannot tolerate indomethacin, whether because of stomach problems, kidney disease, cardiovascular risk, or allergies. For these people, finding an alternative is genuinely difficult, because no other drug works as reliably. The most consistent evidence points to three categories of substitutes: acemetacin (a prodrug closely related to indomethacin), selective COX-2 inhibitors like celecoxib, and certain anticonvulsants.16PubMed Central. How can you manage an indomethacin-responsive headache in someone who cannot take indomethacin?
Among anticonvulsants, topiramate has the strongest track record. In a critical appraisal of treatment data, topiramate showed a complete response in roughly four out of ten patients and at least partial improvement in about three-quarters.17PubMed Central. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal Those numbers fall well short of indomethacin’s near-universal effectiveness, but they represent real options when the first-line drug is off the table.
For truly refractory cases where medications have failed, neuromodulation has emerged as a last-resort option. A case report documented a patient with chronic paroxysmal hemicrania treated with an occipital nerve stimulator after being unable to tolerate indomethacin. Over more than ten years of follow-up, the patient experienced a sustained reduction of more than 50% in attack frequency, was eventually pain-free, and was able to stop indomethacin entirely.18Headache. Occipital Nerve Stimulation for Medically Refractory Chronic Paroxysmal Hemicrania This is a single case, not a trial, but it gives some hope that interventional approaches can work when drugs don’t.
Paroxysmal Hemicrania in Children
The condition is typically discussed as an adult disorder, but it does occur in children and adolescents. A systematic review of pediatric cases found onset as early as age one, with a mean onset of about six and a half years and a mean age of diagnosis closer to eight years, reflecting a diagnostic gap of roughly two years even in recognized cases.19PubMed. Paroxysmal hemicrania in children and adolescents: A systematic review
The clinical picture in children closely mirrors the adult version: severe unilateral pain with autonomic symptoms on the same side and a strong response to indomethacin. Left-sided pain was twice as common as right-sided in the pediatric cases reviewed. Interestingly, the boy-to-girl ratio in children was roughly even (slightly more boys), in contrast to the female predominance seen in adults.20PubMed. Paroxysmal hemicrania in children and adolescents: A systematic review Standard adult diagnostic criteria appear to apply well to children, and a clinic-based study confirmed that the International Headache Society classification worked for pediatric patients, with similar pain characteristics, autonomic symptoms, and treatment response.21PubMed. Paroxysmal hemicrania in children–symptoms, diagnostic criteria, therapy and outcome
Using indomethacin in children does raise practical concerns, particularly around gastrointestinal side effects and the lack of large pediatric safety studies. Most reported cases responded well to indomethacin, though some children needed a combination approach with additional medications.22PubMed. Paroxysmal hemicrania in children and adolescents: A systematic review
Episodic Versus Chronic Forms
Paroxysmal hemicrania comes in two recognized patterns. The chronic form features attacks occurring daily or near-daily for more than a year without a remission period lasting longer than three months. The episodic form involves bouts of frequent attacks separated by pain-free stretches that last at least three months. Most patients in clinical series have the chronic form, though that may partly reflect referral bias: people with episodic patterns whose symptoms remit on their own are less likely to be sent to a headache specialist and therefore less likely to appear in the published literature.
Both forms respond to indomethacin. Some patients shift between episodic and chronic patterns over their lifetime, and a few people with the episodic form eventually develop chronic disease. Because indomethacin works so reliably regardless of subtype, the practical distinction matters less for treatment than it does for understanding the natural history and long-term planning around medication use. If you have the episodic type, your doctor may try tapering off indomethacin during remission periods to avoid unnecessary drug exposure.
Secondary Cases and Structural Mimics
Most paroxysmal hemicrania is “primary,” meaning it arises on its own without an underlying structural cause. Rarely, the exact same pattern of short, frequent, side-locked attacks with autonomic features and an indomethacin response can appear as a secondary phenomenon caused by something else in the brain. Case reports have linked the paroxysmal hemicrania phenotype to pituitary tumors, brain lesions, and vascular abnormalities, among other causes. These secondary cases are the reason headache guidelines recommend brain imaging in anyone newly diagnosed with the condition. The imaging is usually normal, but when it’s not, identifying a structural cause can change management entirely.
The red flags that should prompt faster imaging include a new onset at an unusual age (particularly in older adults with no headache history), progressive worsening despite indomethacin, atypical features like bilateral symptoms, and any accompanying neurological deficits like weakness or vision changes that aren’t part of the autonomic symptom cluster.
Living with the Condition
Trigeminal autonomic cephalalgias as a group are recognized as severely disabling headache disorders.23PubMed. Ventral tegmental area deep brain stimulation for trigeminal autonomic cephalalgias: a comprehensive literature review Even with indomethacin providing excellent pain control for most people, the chronic nature of the condition means living with a long-term medication regimen and the anxiety of breakthrough attacks during dose adjustments or missed pills. Patients frequently report that the unpredictability before diagnosis was the worst part: attacks striking without warning during meetings, while driving, in the middle of the night. Once diagnosed and treated, the transformation can be swift and profound, but getting to that point often takes years of wrong diagnoses and failed treatments.
Attack triggers are not well studied in paroxysmal hemicrania compared to, say, cluster headache. Some patients identify mechanical triggers like bending the head or pressing on certain neck areas, while others notice attacks clustering around periods of stress or fatigue. But many attacks appear to come out of nowhere, which aligns with the hypothalamic-generator theory: if the attacks originate from deep brain rhythms rather than peripheral triggers, there may simply not be avoidable external triggers for most people.
If you suspect you have paroxysmal hemicrania, the most productive step is to seek evaluation by a headache specialist and explicitly discuss an indomethacin trial. The condition’s responsiveness to that single drug is unusual in medicine: it’s both the strongest treatment and the most definitive diagnostic test, and for the majority of people who have it, it transforms a disabling headache disorder into a manageable one.